BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsCompany update

ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent

Related news

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-05-07 20:01 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

DGXQuest Diagnostics2026-06-29 12:16 EST

Quest Diagnostics Foundation Commits Nearly $5 Million to Improving Health Outcomes and Food Security in Miami-Dade County, Florida

DGXQuest Diagnostics2026-09-16 12:03 EST

Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

LUCDLucid Diagnostics2026-04-30 12:31 EST

Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

FLGTFulgent Genetics, Inc.2026-03-17 20:31 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2025-12-22 21:10 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

BDSXBiodesix2026-09-14 20:01 EST

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

BIAFbioAffinity Technologies, Inc.2026-07-22 12:08 EST

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

View all latest news

Bluejay Diagnostics

Critical-Care Diagnostics Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform. Symphony Platform Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow. Symphony IL-6...

Recent company news

BJDXBluejay Diagnostics2026-09-08 10:30 EST

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Stock data

Close
0.85 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States